-
Product Insights
NewOcclusive Arterial Disease (OAD) – Drugs In Development, 2024
Empower your strategies with our Occlusive Arterial Disease (OAD) – Drugs In Development, 2024 report and make more profitable business decisions. Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such...
-
Product Insights
NewPeripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may...
-
Product Insights
NewDiastolic Heart Failure – Drugs In Development, 2024
Empower your strategies with our Diastolic Heart Failure (HFpEF) – Drugs In Development, 2024 report and make more profitable business decisions. Diastolic heart failure, also known as heart failure with preserved ejection fraction, is a condition in which the heart's main pumping chamber becomes stiff and unable to fill properly. One of the two types of left-sided heart failure is diastolic heart failure. Main causes include high blood pressure, diabetes, coronary artery disease, and obesity. Untreated diastolic heart failure has the...
-
Product Insights
NewThromboembolism – Drugs In Development, 2024
Empower your strategies with our Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. A thromboembolism occurs when a blood clot (thrombus) break and travels in the bloodstream. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery. The Thromboembolism drugs in development market research report provide comprehensive information...
-
Product Insights
NewAtrial Fibrillation – Drugs In Development, 2024
Empower your strategies with our Atrial Fibrillation – Drugs In Development, 2024 report and make more profitable business decisions. Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery. The Atrial Fibrillation drugs in development market research...
-
Product Insights
NewHypertrophic Cardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Hypertrophic Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise; sensation of rapid, fluttering or pounding heartbeats; and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers, and blood thinners. The...
-
Product Insights
NewDilated Cardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Dilated Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and...
-
Product Insights
NewPulmonary Arterial Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
NewThrombosis – Drugs In Development, 2024
Empower your strategies with our Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a...
-
Product Insights
NewPre-Eclampsia – Drugs In Development, 2024
Empower your strategies with our Pre-Eclampsia – Drugs In Development, 2024 report and make more profitable business decisions. Hypertension during pregnancy is termed pre-eclampsia. It generally occurs during the second trimester or after giving birth. Although there is no exact cause but stress, abnormal placentation is believed to lead to pre-eclampsia. Obesity, underlying diseased conditions hypertension, diabetes, kidney disease, or genetic causes may also lead to this. When pathologically examined high levels of protein in the urine (proteinuria), renal insufficiency, and...